SCHEMBL9905968

SCHEMBL9905968

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC1COP(=O)(O)O1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.43
PGR P06401 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
PTGS2 P35354 1/20 0.43
PDE4D Q08499 1/20 0.43
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
FFAR1 O14842 1/20 0.39
MAPT P10636 1/20 0.39
CYP19A1 P11511 1/20 0.39
RXRA P19793 1/20 0.39
PPARG P37231 1/20 0.39
OXER1 Q8TDS5 1/20 0.39
LPAR1 Q92633 1/20 0.37
LPAR3 Q9UBY5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9905963 0.93 ADORA3 (0.53) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL9905965 0.91 ALDH1A1 (0.55) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL9905967 0.90 MGLL (0.45) ALDH1A1MAPTLPAR1LPAR3
SCHEMBL29651433 0.84 LPAR1 (0.52) LPAR1LPAR3
SCHEMBL17482404 0.80 LPAR1 (0.55) LPAR1LPAR3
SCHEMBL29372509 0.80 LPAR1 (0.55) LPAR1LPAR3
SCHEMBL4346551 0.78 NR1I2 (0.44) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL4954030 0.78 NR1I2 (0.44) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL9905953 0.76 ALDH1A1 (0.43) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL17320970 0.76 LPAR1 (0.62) LPAR1LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9101563-B2 Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof SCF PHARMA INC (CA) 2015-08-11 US disclosed
US-9101563-B2 Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof SCF PHARMA INC (CA) 2015-08-11 US disclosed
US-20150057348-A1 METHODS FOR TREATING INFLAMMATORY DISEASES WITH COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2015-02-26 US disclosed
US-20150057348-A1 METHODS FOR TREATING INFLAMMATORY DISEASES WITH COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2015-02-26 US disclosed
US-20120208884-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2012-08-16 US disclosed
US-8222295-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2012-07-17 US disclosed
US-8222295-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2012-07-17 US disclosed
US-8198324-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2012-06-12 US disclosed
US-8198324-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2012-06-12 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
WO-2008113177-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN NR1I2 2216/4885PGR 1737/4885ADORA3 1612/4885
US-20120208884-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN NR1I2 2226/4885PGR 1781/4885ADORA3 1652/4885
US-20150057348-A1 METHODS FOR TREATING INFLAMMATORY DISEASES WITH COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF PPARG, PTGES, PTGIS NR1I2 2550/4885PGR 4369/4885ADORA3 1560/4885
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF PPARG, PTGES, PTGIS NR1I2 2641/4885PGR 4113/4885ADORA3 1724/4885
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN NR1I2 2216/4885PGR 1737/4885ADORA3 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.